	C 2012 Mar 31	R 2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	C 2012 Mar 31	R 2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M IR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS	12M IR
Total Revenue	55.13	56.11	56.71	57.39	53.59	63.45	62.85	77.99	85.97	97.55	112.27	92.83	108.53	110.19	105.81	110.63
Cost of Operating Revenue	43.98	41.10	45.70	46.08	31.55	42.40	42.88	56.21	58.43	65.98	77.74	60.90	74.23	76.64	76.39	84.63
Gross Profit	11.15	15.01	11.00	11.32	22.04	21.05	19.96	21.78	27.54	31.57	34.52	31.93	34.30	33.55	29.42	26.00
Gross Margin	20.2	26.7	19.4	19.7	41.1	33.2	31.8	27.9	32.0	32.4	30.8	34.4	31.6	30.4	27.8	23.5
Total Operating Expenses	53.56	57.85	59.80	60.04	47.59	59.12	61.99	79.96	85.78	91.09	103.26	86.08	102.38	107.59	104.61	113.98
Operating Profit	1.57	-1.74	-3.10	-2.65	6.00	4.33	0.85	-1.97	0.19	6.47	9.00	6.75	6.15	2.60	1.20	-3.35
Operating Margin	2.8	-3.1	-5.5	-4.6	11.2	6.8	1.4	-2.5	0.2	6.6	8.0	7.3	5.7	2.4	1.1	-3.0
Financing Income/(Expense) - Net	-1.25	-1.94	-1.58	-1.70	-1.45	-1.71	-1.07	-0.57	-0.20	-0.08	-0.22	2.96	2.94	3.04	-0.26	-0.32
Profit before Taxes	0.84	-3.21	-4.95	-2.71	9.74	5.64	4.64	2.76	2.91	10.79	19.56	15.89	20.68	25.67	16.70	5.91
Income Taxes	0.31	1.16	0.20	-1.31	2.89	3.12	1.83	1.74	1.05	3.54	5.47	3.31	3.91	6.16	1.69	1.53
Profit after Tax	0.53	-4.37	-5.15	-1.40	6.85	2.52	2.81	1.01	1.85	7.25	14.09	12.58	16.78	19.50	15.01	4.38
PAT Margin	1.0	-7.8	-9.1	-2.4	12.8	4.0	4.5	1.3	2.2	7.4	12.6	13.6	15.5	17.7	14.2	4.0
EPS - Basic - ex Extraordinary Items	0.25	-2.08	-2.45	-0.66	3.25	1.20	1.33	0.48	0.88	3.44	6.70	5.98	7.97	9.27	7.13	2.10
EPS - Diluted - ex Extraordinary Items	0.25	-2.08	-2.45	-0.66	3.25	1.20	1.33	0.48	0.88	3.44	6.70	5.98	7.97	9.27	7.13	2.10
EBIT	1.57	-1.74	-3.10	-2.65	6.00	4.33	0.85	-1.97	0.19	6.47	9.00	6.75	6.15	2.60	1.20	-3.35
EBITDA	2.57	2.99	5.96	3.42	6.83	7.11	3.92	1.14	3.36	7.70	10.66	8.08	8.11	4.80	3.29	-1.09
EBITDA Margin	4.7	5.3	10.5	6.0	12.7	11.2	6.2	1.5	3.9	7.9	9.5	8.7	7.5	4.4	3.1	-1.0

Balance Sheet

Abridged

Understanding Balance Sheet

Alpa Laboratories Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	C 2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	C 2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	60.93	43.73	52.76	112.63	125.22	104.63	97.72	94.09	95.46	121.09	138.94	149.13	160.98	192.49	210.90
Long-Term Investments	-	-	-	10.10	4.06	8.98	12.88	19.06	17.73	10.49	6.98	7.77	8.27	8.77	11.09
Property Plant & Equipment - Net	68.26	79.99	73.11	4.87	4.53	5.18	6.12	5.88	7.23	8.73	9.22	6.96	11.41	20.60	20.12
Total Non-Current Assets	69.08	80.84	73.95	15.68	17.37	20.90	23.80	27.13	25.89	19.28	16.30	18.14	21.39	30.14	31.25
Total Assets	130.01	124.57	126.71	128.31	142.59	125.53	121.52	121.22	121.35	140.37	155.24	167.27	182.37	222.63	242.14
Total Current Liabilities	28.57	22.52	32.30	41.24	49.78	29.71	23.36	22.31	20.79	32.50	31.38	29.63	28.07	46.70	52.53
Long Term Debt	2.67	6.20	4.20	-	-	0.47	0.61	0.41	0.19	0.01	2.12	0.78	-	-	-
Total Non-Current Liabilities	3.61	8.58	6.11	0.51	0.60	1.09	0.61	0.41	0.19	0.23	2.12	3.06	2.40	4.49	3.34
Total Liabilities	32.18	31.10	38.40	41.75	50.38	30.80	23.98	22.72	20.98	32.73	33.51	32.69	30.46	51.19	55.86
Total Shareholders' Equity	97.83	93.46	88.31	86.56	92.21	94.73	97.55	98.49	100.37	107.64	121.73	134.58	151.91	171.43	186.28
Total Equity	97.83	93.46	88.31	86.56	92.21	94.73	97.55	98.49	100.37	107.64	121.73	134.58	151.91	171.43	186.28
Total Liabilities & Equity	130.01	124.57	126.71	128.31	142.59	125.53	121.52	121.22	121.35	140.37	155.24	167.27	182.37	222.63	242.14

Cash Flow

Abridged

Understanding Cash Flow Statement

Alpa Laboratories Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	R 2015 Mar 31	2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	R 2015 Mar 31	2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	1.77	1.27	4.48	5.83	10.00	5.77	6.86	4.67	9.06	9.35	9.80	10.71	9.91	8.21	5.09
Working Capital - Increase/(Decrease)	-4.00	-0.48	1.49	-6.63	-28.49	13.85	-16.34	-2.39	10.15	-10.33	1.45	-0.80	-4.06	12.28	7.35
Net CF from Operating Activities	-2.23	0.79	5.97	-0.80	-18.49	19.62	-9.48	2.28	19.21	-0.98	11.25	9.91	5.85	20.50	12.44
Capital Expenditures - Net	-1.16	3.85	2.19	1.17	10.61	1.41	1.97	0.85	2.55	2.84	2.19	1.13	6.39	11.38	3.95
Net CF from Investing Activities	-0.92	-3.85	-2.19	34.90	-12.67	-5.98	-15.76	-18.52	-12.79	5.07	-17.14	0.90	-15.90	-14.77	-14.30
Debt - LT & ST - Issuance/(Retirement) - Total	2.45	3.53	6.01	8.32	-4.34	-13.60	0.14	-0.20	-0.22	-0.18	5.66	-3.57	2.94	-5.21	2.47
Net Cash Flow from Financing Activities	2.45	3.53	6.01	8.32	-4.34	-13.60	9.90	-4.21	-1.15	0.26	5.66	-3.57	2.94	-5.21	2.48
Free Cash Flow to Equity	1.37	0.48	9.79	6.35	-33.44	4.61	-11.31	1.23	16.45	-4.00	14.72	5.22	2.41	3.91	10.96
Free Operating CF net dividend	-2.77	-3.09	3.78	-1.96	-29.10	18.21	-11.45	1.43	16.67	-4.19	9.06	8.78	-0.53	9.12	8.48
Free Operating CF	-2.77	-3.09	3.78	-1.96	-29.10	18.21	-11.45	1.43	16.67	-4.19	9.06	8.78	-0.53	9.12	8.48

Business Segment Analysis

FY End:

Mar 25

Alpa Laboratories Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Drugs & Chemicals (100.0%)₹ 11.38 Cr

Revenue / Sales

Drugs & Chemicals (100.0%)₹ 110.19 Cr

Assets

Drugs & Chemicals (100.0%)₹ 222.63 Cr

Operating Income

Drugs & Chemicals (100.0%)₹ 2.60 Cr

Regional Segment Analysis

FY End:

Mar 14

Alpa Laboratories Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Domestic (72.4%)₹ 41.07 CrExports (27.6%)₹ 15.64 Cr

Historical Segment Analysis

Track how Alpa Laboratories Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2023 Mar 31	2024 Mar 31	2025 Mar 31
	2023 Mar 31	2024 Mar 31	2025 Mar 31
Drugs & Chemicals	1	6	11

Frequently Asked Questions

What is the revenue of Alpa Laboratories Ltd.?

The latest trailing twelve month revenue of Alpa Laboratories Ltd. is ₹ 110.63 Cr, reflecting a 1-year growth of 0.46% and a 3-year CAGR of 4.85%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Alpa Laboratories Ltd.?

The latest trailing twelve month net profit (PAT) of Alpa Laboratories Ltd. is ₹ 4.38 Cr, with a 3-year earnings CAGR of -30.12%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Alpa Laboratories Ltd.?

The trailing twelve month EBITDA of Alpa Laboratories Ltd. is approximately ₹ 1.25 Cr (based on an operating margin of 1.13%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Alpa Laboratories Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Alpa Laboratories Ltd. is 2.10. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Alpa Laboratories Ltd.?

The debt-to-equity ratio of Alpa Laboratories Ltd. stands at 0.01. The interest coverage ratio is -10.44x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Alpa Laboratories Ltd.?

The estimated book value per share of Alpa Laboratories Ltd. is 86.88 (derived from a P/B ratio of 0.71 and market price of ₹ 62.02), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Alpa Laboratories Ltd.?

The trailing twelve month operating cash flow of Alpa Laboratories Ltd. is ₹ 12.44 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Alpa Laboratories Ltd. report consolidated or standalone financials?

Alpa Laboratories Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.